Reshaping the HIV treatment and prevention landscape
Investing to drive step-change in growth and business mix
Vaccines and
Specialty
Medicines
prioritised
Changing business sales mix
2021-26 sales growth CAGR
Illustrative
Vaccines: high single-digit %
Specialty Medicines: double-digit %
General
Medicines
optimised
General Medicines: broadly stable
2017
Vaccines
Specialty Medicines
General Medicines
2021
2026
gsk
All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates. See basis of preparation and assumptions in Appendix. 2021-
26 CAGR is for the 5 years to 2026, using 2021 as the base year. Pipeline sales are risk-adjusted and include anticipated sales of new products and Life Cycle Innovation (LCI) launched from 2021 onwards. Note: COVID therapeutic and
vaccine solutions are excluded from the above.
15View entire presentation